<?xml version="1.0" encoding="UTF-8"?>
<p id="p0010">At present, synthetic agents such as pentavalent antimonies (Glucantime® and Pentostam®) and various other drugs such as amphotericin B, paromomycin, miltefosine, pentamidine, allopurinol and azole deravatives are used as the first-line and/or second-line alone or in combination for treatment of different types of leishmaniasis. However, the application of these drugs is limited due to low efficacy, high toxicity index, and induction of parasite resistance, long duration of action and high costs (
 <xref rid="bb0050" ref-type="bibr">Croft et al., 2006</xref>). Such limitations for use of chemical drugs emphasize an urgent need for discovery of new medicinal alternatives with different mechanism of action, greater potency, shorter treatment cycles, inexpensiveness and availability in endemic countries (
 <xref rid="bb0085" ref-type="bibr">Lamidi et al., 2005</xref>).
</p>
